More than one-third of children with severe juvenile idiopathic arthritis showed a 90 percent improvement after 12 months of therapy with the TNF-inhibitor Enbrel (etanercept), and nearly half reached a state of minimal disease activity, according to a U.K. study.

Click here for more.